Japanese Heart Journal · 1980 · 17 citations · 17 references
MedicineCardiologyPharmacotherapyCardiovascular PharmacotherapyRenal PathophysiologyRenal PharmacotherapyHypertension ControlHypertension ManagementHypertension PharmacotherapyRenal HemodynamicsRenal PharmacologyRenovascular Hypertension EvaluationAngiotensin-converting Enzyme Inhibition TestingAtherosclerotic Renal Artery StenosisCaptopril TherapyHypertensive Renal HemodynamicsPlasma Renin ActivityRenin-angiotensin System InhibitorsRenin-angiotensin-aldosterone System InhibitionRenin-angiotensin-aldosterone System Inhibitors
Captopril (SQ 14225), an orally active converting enzyme inhibitor, was administered in a dose of 50 mg to 12 normotensive subjects (Group I), 26 essential hypertensive patients (Group II), and 8 renovascular hypertensive patients (Group III). In Group III, 5 of the 8 patients had control plasma renal activity (PRA) similar to those in Groups I and II patients, but the PRA response to the administration of captopril was greater in 7 of the 8 patients than those in Groups I and II. These 7 patients had either bilateral or unilateral main renal artery stenosis. Captopril caused no increase in PRA in the remaining 1 who had unilateral renal artery stenosis with contralateral renin aplasia. It is concluded that this provocation test is useful as a screening procedure for the diagnosis of renovascular hypertension.
17
David B. Case, Steven A. Atlas, John H. Laragh et al. · Progress in Cardiovascular Diseases · 1978 · 366 citations
Medicine, Cardiology, Pharmacology +16
A SPECIFIC ORALLY ACTIVE INHIBITOR OF ANGIOTENSIN-CONVERTING ENZYME IN MAN
RogerK. Ferguson, Hans-R. Brunner, GustaveA. Turini et al. · The Lancet · 1977 · 325 citations